Corporate / M&A

IP / IT

Windward Bio_we_640x140

Homburger News

Share-Image Teamplate Deals-and-Cases

On January 10, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200 m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia.
Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
Homburger AG advises Windward Bio on its set-up and financing. The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Huber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&amp;A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).

Homburger advises Windward Bio on its USD 200 m Series A Financing

Financing and Investment Products

Regulatory

Towerbrook_grey_640x140

Homburger advised TowerBrook Capital Partners, a London and New York-based investment company, on its acquisition of a majority stake of the IDAK Food Group. The management team of IDAK Food Group retains a minority stake. IDAK Food Group is a strongly networked group of specialized companies and manufacturers in the premium frozen food sector.
The Homburger team was led by Anna Peter (Corporate / M&amp;A) and Jürg Frick (Financing and Investment Products) and included Héloïse de Jamblinne, Alessandra Dumitru and Carolina Rodriguez (all Corporate / M&amp;A), Nathalie Scherrer (Financing and Investment Products), Reto Heuberger and Juliette Buob (all Tax) as well as Richard Stäuber, Andreas Burger and Christoph Grüninger (all Regulatory).

Homburger advised TowerBrook Capital Partners on its acquisition of IDAK Food Group

Dali Discount AG_web_640x140

Swiss-based DALI DISCOUNT AG, a leading hard discounter in Southeast Asia, has received multiple equity financings as part of its Series C financing round and its previous financing round from Navegar, Creador, Venturi Partners, the Asian Development Bank, DEG – Deutsche Investitions- und Entwicklungsgesellschaft and other institutional investors.
DALI DISCOUNT operates the first and fastest-growing hard discounter in Southeast Asia and provides quality everyday goods at low prices in its stores.
The Homburger team comprises Andreas Müller, Oliver Kneubühl, Carlo Sulser, Oriana Schöni and Carolina Rodriguez (all Corporate / M&amp;A) and Stefan Oesterhelt and Laetitia Fracheboud (both Tax).

Homburger advises DALI DISCOUNT AG in connection with its Series C financing round and its previous financing round

Carolina
Rodríguez

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advised TowerBrook Capital Partners on its acquisition of IDAK Food Group

Homburger advises DALI DISCOUNT AG in connection with its Series C financing round and its previous financing round

Join the Team

Carolina Rodríguez

Career

Languages

Teams

CarolinaRodríguez

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advised TowerBrook Capital Partners on its acquisition of IDAK Food Group

Homburger advises DALI DISCOUNT AG in connection with its Series C financing round and its previous financing round

Join the Team

Carolina Rodríguez

Career

Languages

Teams

Carolina
Rodríguez